Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395974 | 0.80 | ALDH1A1 (0.46) | NISCHALDH1A1TDP1TSHRPKM | |
| SCHEMBL141600 | 0.80 | ALDH1A1 (0.46) | NISCHALDH1A1TDP1TSHRPKM | |
| SCHEMBL1626317 | 0.76 | NISCH (1.00) | NISCH | |
| SCHEMBL4543645 | 0.76 | ADRA2A (0.54) | NISCHALDH1A1TDP1 | |
| SCHEMBL11847292 | 0.76 | ALDH1A1 (0.78) | ALDH1A1TDP1TSHRPKMLMNA | |
| SCHEMBL30163845 | 0.74 | PDCD1LG2 (0.47) | NISCHPDCD1LG2CD274 | |
| SCHEMBL4383292 | 0.74 | NISCH (0.70) | NISCHPDCD1LG2CD274 | |
| SCHEMBL10651765 | 0.71 | L3MBTL1 (0.48) | NISCHALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL9654041 | 0.71 | ADRA2A (0.46) | NISCHALDH1A1TDP1TSHR | |
| SCHEMBL4821629 | 0.71 | NISCH (0.64) | NISCHPDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629463-B2 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080132524-A1 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | CLARK DAVID ALAN | 2008-06-05 | — | — | US | disclosed |
| US-7375232-B2 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1417204-B1 | ORTHO-HETEROCYCLIC SUBSTITUTED ARYL AMIDES FOR CONTROLLING INVERTEBRATE PESTS | DU PONT (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040242645-A1 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1417204-A1 | ORTHO-HETEROCYCLIC SUBSTITUTED ARYL AMIDES FOR CONTROLLING INVERTEBRATE PESTS | E. I. du Pont de Nemours and Company (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003016304-A1 | ORTHO-HETEROCYCLIC SUBSTITUTED ARYL AMIDES FOR CONTROLLING INVERTEBRATE PESTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132524-A1 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | AOC2, DDT, CBR3 | NISCH 53/4885ALDH1A1 1998/4885TDP1 3431/4885 |
| US-20040242645-A1 | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests | AOC2, OLA1, AOC3 | NISCH 17/4885ALDH1A1 1639/4885TDP1 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.